Cardiovascular Systems (NASDAQ:CSII) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cardiovascular Systems (NASDAQ:CSII – Get Rating) in a research note published on Saturday morning. The firm issued a hold rating on the medical device company’s stock.

Several other research analysts have also commented on the stock. Lake Street Capital lowered shares of Cardiovascular Systems from a buy rating to a sell rating in a research note on Thursday, February 9th. Barclays initiated coverage on shares of Cardiovascular Systems in a research note on Wednesday, December 21st. They set an equal weight rating and a $15.00 price target on the stock.

Cardiovascular Systems Trading Up 0.1 %

Cardiovascular Systems stock traded up $0.02 during trading hours on Friday, hitting $19.76. The company had a trading volume of 1,312,942 shares, compared to its average volume of 845,441. The company has a quick ratio of 4.92, a current ratio of 6.04 and a debt-to-equity ratio of 0.08. The firm’s fifty day moving average is $17.01 and its 200-day moving average is $14.95. Cardiovascular Systems has a fifty-two week low of $12.26 and a fifty-two week high of $23.47.

Cardiovascular Systems (NASDAQ:CSII – Get Rating) last announced its quarterly earnings results on Wednesday, February 8th. The medical device company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). Cardiovascular Systems had a negative return on equity of 15.39% and a negative net margin of 15.79%. The business had revenue of $61.45 million for the quarter, compared to analyst estimates of $63.06 million. During the same quarter last year, the company earned ($0.23) EPS. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. Research analysts anticipate that Cardiovascular Systems will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd acquired a new position in Cardiovascular Systems in the 2nd quarter valued at $34,000. HighMark Wealth Management LLC bought a new stake in Cardiovascular Systems in the 4th quarter valued at $35,000. Quadrant Capital Group LLC boosted its holdings in Cardiovascular Systems by 179.2% in the 4th quarter. Quadrant Capital Group LLC now owns 2,993 shares of the medical device company’s stock valued at $41,000 after purchasing an additional 1,921 shares during the period. Performa Ltd US LLC boosted its holdings in Cardiovascular Systems by 60.5% in the 4th quarter. Performa Ltd US LLC now owns 3,450 shares of the medical device company’s stock valued at $47,000 after purchasing an additional 1,300 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Cardiovascular Systems by 105.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 4,670 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 2,394 shares during the period. 86.61% of the stock is currently owned by institutional investors and hedge funds.

Cardiovascular Systems Company Profile

(Get Rating)

Cardiovascular Systems, Inc is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St.